Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 46%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is well-situated for long-term growth, with strong organic revenue growth driven by their musculoskeletal solutions and enabling technologies businesses, and a presence in both the United States and international markets. Additionally, the company's financials are strong, with reported earnings beats and margin expansion. Their diversified product offerings, including their spinal robotics platform, ExcelsiusGPS, are driving market share gains and attracting new customers. Factors such as the increasing demand for spinal robotics and the company's expansion into other medical fields, such as trauma and large joint robotics, provide further upside potential for Globus Medical's growth and profitability.

Bears say

Globus Medical is experiencing a decrease in revenue due to integration initiatives impacting their sales and marketing teams, and this is expected to continue throughout the year. Additionally, there is uncertainty surrounding their merger with NuVasive and potential competition from larger medical device companies. This, coupled with potential staffing shortages and macroeconomic headwinds, may result in a decline in revenue and margins, leading to a negative outlook on their stock.

Globus Medical (GMED) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 46% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 13 analysts, Globus Medical (GMED) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.